Predicting response to epigenetic therapy

TY - JOUR

T1 - Predicting response to epigenetic therapy

AU - Treppendahl, Marianne B

AU - Sommer Kristensen, Lasse

AU - Grønbæk, Kirsten

PY - 2014/1/2

Y1 - 2014/1/2

N2 - Drugs targeting the epigenome are new promising cancer treatment modalities; however, not all patients receive the same benefit from these drugs. In contrast to conventional chemotherapy, responses may take several months after the initiation of treatment to occur. Accordingly, identification of good pretreatment predictors of response is of great value. Many clinical parameters and molecular targets have been tested in preclinical and clinical studies with varying results, leaving room for optimization. Here we provide an overview of markers that may predict the efficacy of FDA- and EMA-approved epigenetic drugs.

AB - Drugs targeting the epigenome are new promising cancer treatment modalities; however, not all patients receive the same benefit from these drugs. In contrast to conventional chemotherapy, responses may take several months after the initiation of treatment to occur. Accordingly, identification of good pretreatment predictors of response is of great value. Many clinical parameters and molecular targets have been tested in preclinical and clinical studies with varying results, leaving room for optimization. Here we provide an overview of markers that may predict the efficacy of FDA- and EMA-approved epigenetic drugs.

KW - Antineoplastic Agents

KW - DNA Methylation

KW - Drug Resistance, Neoplasm

KW - Epigenesis, Genetic

KW - Gene Expression Regulation, Neoplastic

KW - Histone Deacetylase Inhibitors

KW - Humans

KW - Molecular Targeted Therapy

KW - Neoplasms

KW - Prognosis

KW - Treatment Outcome

KW - Tumor Markers, Biological

U2 - 10.1172/JCI69737

DO - 10.1172/JCI69737

M3 - Review

C2 - 24382389

SN - 0021-9738

VL - 124

SP - 47

EP - 55

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

IS - 1

ER -